Importance

Loading Importance Indicators...

Abstract

A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is --CONH-- or --NR.sup.1CO-- wherein R.sup.1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: wherein R.sup.2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, --NH-- or D is a bond, --CS-- or --CO--; E is a bond or --NH--; F is a bond, --CO--, --O-- or --SO.sub.2--; and G is lower alkyl, optionally protected amino, --OH, phenyl, R.sup.3 is lower alkyl, provided that when Z is a group of the formula: then G should not be amino, when Z is a group of the formula: then G should not be when Z is a group of the formula: and G is optionally protected amino, then D should be --CS--, or then A should be lower alkylene, B or E should be --NH-- and F should be --CO--; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

Loading the Abstract Image...

First Claim